Aim: To explore the association between cardiovascular medication use and cognitive impairment in adults aged 50 years and over. 
| INTRODUCTION
Cognitive impairment is common among older adults, can range from mild to severe, and is characterized by deterioration in memory, attention, learning, reaction time, and executive function. 1, 2 Cognitive impairment adversely affects independence, including the ability to adhere to prescribed treatments and medications, which can further impact health. 2, 3 Midlife cardiovascular risk factors, including hypertension and dyslipidemia, have been associated with an increased risk of cognitive decline in later life. 3 Associations between cardiovascular risk factors and cognitive impairment have also been reported cross-sectionally, suggesting that appropriate risk factor management may reduce the risk of cognitive impairment. [4] [5] [6] [7] [8] However, while observational studies have reported associations between cardiovascular risk factors and cognition, clinical trial evidence on whether risk factor treatment through the use of cardiovascular medications could delay cognitive decline remains inconclusive. 3, 5, 7 While some studies have reported potential adverse cognitive effects of some cardiovascular medications, including statins, 9 a meta-analysis of placebo-controlled RCTs reporting cognitive outcomes found no evidence of adverse effects of statins on cognitive function in participants who were either cognitively normal or who had Alzheimer's disease. 10 Similarly, an RCT investigating the effects of withdrawal of antihypertensive treatment on cognitive functioning of persons aged 75 and older found that discontinuation of antihypertensive medications did not improve cognitive function. A recent review concluded that trial evidence for the beneficial effect of lowering blood pressure or cholesterol on cognitive decline is weak. 11 However, a number of methodological problems were noted, including variability in cognitive assessments, clinical endpoints and inclusion criteria, high numbers of actively treated persons in control arms, high discontinuation rates, and shorter follow-up periods. 3, 5, 11 Finally, poor medication adherence may attenuate treatment effects, with some clinical trials reporting adherence rates of 43% to 78%.
12,13
| Cognitive impairment and cardiovascular medication use
Medication adherence is essential for managing chronic conditions, as nonadherence is associated with increased morbidity, mortality, and higher costs of care. [14] [15] [16] [17] However, adherence to cardiovascular medications is often poor, with a meta-analysis of 20 studies reporting an adherence estimate of 57% (95% CI 50, 64). 18 Medication adherence requires various cognitive skills, including scheduling medications, understanding directions, and problem-solving in relation to missed doses, all of which can be adversely affected by cognitive impairment. 14, 19 Poor adherence could in turn lead to further cognitive decline, as well as increasing the risk of cardiovascular events and stroke. 6, 12 Given the prevalence of suboptimal adherence, it is important to consider the extent to which patients actually adhere to medications when assessing the impact of drug treatment on outcomes.
| Aim
The aim of this study was to explore the association between cardiovascular medication use and cognitive impairment in a populationbased cross-sectional study of community-dwelling adults aged 50 years and over.
| METHODS

| Design and data sources
This cross-sectional linked database study involved secondary quantitative analysis of a subsample of participants from wave 1 of the Irish Longitudinal Study on Ageing (TILDA), 20, 21 with available data on dispensed prescription medications from the Irish Health Service
Executive Primary Care Reimbursement Service (HSE-PCRS) pharmacy claims database. This database provides details on monthly dispensed medications for each individual in the scheme. Access to the scheme, which provides free general practitioner and hospital visits, and prescription medications at minimal cost, is means-tested for persons aged <70 years, with a substantially higher income threshold for over 70s. 22 Over 90% of adults over the age of 70 in Ireland are eligible for the scheme. Members of the scheme are thus representative of the over-70s in Ireland; however, among those under the age of 70, women and those in lower socio-economic groups are over-represented. 23 
| Participants
The target population for wave 1 of The Irish Longitudinal Study had blood pressure measurements and blood lipid profiles, forming the sample for this analysis ( Figure 1 ). As this is a community sample, participants included those prescribed cardiovascular medications for both primary and secondary prevention purposes (for more detailed demographic data on the full TILDA sample, as well as the subsample with available linked prescription claims data, please see Appendix 1).
As the present analysis was limited by the data available for participants in wave 1 of TILDA with cognitive and health assessments and linked prescription claims, a formal power calculation was not conducted.
However, given the sample size of 1903, our study would have sufficient power to detect an odds ratio of 1.36 or greater for the association between medication use and cognitive impairment, assuming a baseline rate of cognitive impairment of 37%, 80% power, and 5% level of significance.
| Cognition
Global cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), a 30-point † tool that assesses attention, orientation, language, verbal memory, visuospatial, and executive function, and can be completed in approximately 10 minutes. 26 The MoCA was developed to detect mild cognitive impairment and is more sensitive than the Mini Mental State Examination when applied to cognitively intact older adults. 26 Several authors have recommended caution when applying the original cut-off of 26 to identify individuals with cognitive impairment, as it has repeatedly yielded low levels of specificity. [27] [28] [29] Indeed, a score of <26 identified more than half of our sample as cognitively impaired.
This is higher than would be expected given the prevalence of cognitive impairment, particularly as participants with severe impairments and dementia were excluded from wave 1 of TILDA. 21, 28 A number of authors have recommended a cut-off of ≤23 to identify individuals with definite impairments in cognitive function. 27, 30, 31 We thus applied this more conservative cut-off in this study.
| Cardiovascular medication use
In order to assess the association between cardiovascular medication use and cognitive impairment, we considered medications commonly used to Medication use in the 365 days prior to TILDA interview was determined using pharmacy claims data, which is commonly used and provides an objective method of estimating medication use for large populations. 13, 17, 18 We calculated the total proportion of days covered (PDC)
as the sum of the days supplied for medications within each medication class divided by the number of days in the study period. 33, 34 At least two prescription fill dates are required for each drug to calculate this ratio.
PDC was capped at 1 (100%, 365 days covered). 15 We used a cut-off of ≥80% to identify good adherence. This cut-off is generally considered sufficient for populations with, or at risk of, cardiovascular disease, presents a reasonable balance between sensitivity and specificity, and has been associated with cardiovascular outcomes. 15, 17, 33, 34 To assess the association between use of antihypertensive, antithrombotic and lipid-modifying medications, and cognitive impairment, respondents were categorized into one of three groups for each of the three medication classes: (1) no medication use (not dispensed any medications; reference group); (2) poor adherence (PDC<80%); and (3) good adherence (PDC ≥80%).
| Health assessment
All participants completed a home or health-center based health assessment, including blood pressure (BP) measurement and complete venous blood lipid profiles. Hypertension was categorized as a mean 
| RESULTS
| Cognitive impairment
Participants who were engaged in lifelong learning, a monthly social activity, or regular physical activity were less likely to be classified as cognitively impaired compared to those not engaged in these activities. Cognitive impairment was also more common among respondents with moderate or severe depressive symptoms, an ADL or IADL disability, and lower levels of education.
In unadjusted analyses, use of antihypertensive medications was significantly associated with cognitive impairment, regardless of whether adherence was good or poor. Good adherence to antithrombotics was associated with cognitive impairment, compared to those who were not using antithrombotic medications. The use of lipidmodifying medications was not associated with cognitive impairment in univariate analyses (Table 1) . 
| Cardiovascular medication use and cognitive impairment
| DISCUSSION
This population-based study of adults aged 50 years and over found no evidence of an independent association between cognitive impair- controlled trials, as follow-up times may be too short to detect an effect on cognition. 11 Longitudinal studies are therefore needed to investigate whether effective cardiovascular risk factor management could modify cognitive decline. 4 Future studies could examine these associations prospectively, as data collection for subsequent waves of TILDA is currently ongoing.
| Strengths and limitations
This study has a number of strengths, including a large sample and objective measures of hypertension and hypercholesterolemia. Our Dispensing data were available for a subsample of all TILDA participants. These participants were older, had less education, lower incomes, and fewer were employed than in the overall TILDA sample. 22 They also reported more chronic diseases, medications, and depressive symptoms. Additionally, participants who did not have cognitive or objective health assessments were more likely to be older and have lower levels of education than those with cognitive and health assessments, which may affect the generalizability of these findings. The fact that cognitive assessments and objective health measures were available for a subsample of respondents may be an indication of the perceived invasiveness or sensitivity of these types of assessments. 38 This is not unique to this study. Mindell et al 38 note that participation rates for survey health examinations in Europe have fallen, with fewer respondents having blood sample, weight, and blood pressure measurements than are interviewed overall. In our study, participants without these assessments were more likely to be older and to have lower levels of education, which may have introduced bias, as both age and education are associated with cognitive function. Finally, people with known or suspected dementia were not recruited for wave 1 of TILDA. 24, 25 Therefore, individuals with more severe forms of cognitive impairment were not included in this study, and the true association between cognitive impairment and (non)use of cardiovascular medications may be underestimated.
In conclusion, given the prevalence of poor adherence to medications for chronic conditions, the extent to which patients actually adhere to medications should be considered when assessing the impact of cardiovascular medication use on outcomes. This is the first study to examine the association between cardiovascular medication use and cognitive impairment using pharmacy claims data linked to a national population cohort. We found no evidence of an independent association between use of antihypertensive, antithrombotic or lipid-modifying medications, and cognitive impairment in this T A B L E 2 Unadjusted and adjusted OR (95% CI) from logistic regression model of cognitive impairment based on exposure to antihypertensives, antithrombotics, and lipid-modifying medications population-based sample of adults aged 50 years and over, irrespective of the level of adherence to these medications.
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